BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 10, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/7 cls
Anika Therapeutics Inc. (NASDAQ:ANIK) Summer Street Mark Landy Price target Buy -18% $9.67
Landy lowered his target to $14 from $21 after FDA upheld a 2010 non-approvable letter for Monovisc to treat osteoarthritis of the knee on an appeal from Anika. The company said it plans to request a meeting with the agency to determine next steps for the single injection device to deliver hyaluronic acid, which is approved in the...

Read the full 557 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >